The groundbreaking research being done in this industry has the potential to change the world. But strict governing regulations may put a damper on company profits and impact investor returns.
What is biotech?
Biotechnology is the research and application of biomolecular processes. These processes are used to create products and technologies designed to help improve our quality of life and support the planet. How? By helping us combat disease, improve the environment, harness clean energy, enhance food production and devise more efficient manufacturing processes.
Each time you take an antibiotic, drink a glass of wine or admire the newest designer dog breed on social media, you’re encountering biotechnology at work.
Biotechnology stocks are stocks from companies that research and produce biotech products, like pharmaceutical drugs, vaccines, biofuels, genetically modified plants, biocatalysts and more.
Why invest in biotech stocks?
Many biotech products — like pharmaceuticals — are a necessity. And staples like these have proven their capacity to weather down markets.
For example, in the first three months of 2020, the S&P 500 dropped by a sizable 26.7%, while the iShares Nasdaq Biotechnology Index ETF — a fund that tracks US biotech and pharmaceutical companies — only lost 15.6%. And in the past year, the same fund has outperformed the S&P 500’s 10.5% return with a 31.6% return of its own.
The COVID-19 pandemic caused many markets to tank. But stocks in companies looking for effective COVID-19 treatments and vaccines have received increased interest — at least for now. This is just one example of the down market resilience of the biotech industry.
Biotech stocks can help balance your portfolio during an economic downturn while providing the opportunity for investors to back groundbreaking technology — technology with the potential to drastically alter and improve our way of life. Biotechnology can and has changed the world — and investors can lend a hand in the process.
Risks of investing in biotech
The primary risk factor for biotech investors is the long, arduous and costly process of bringing a concept through research and development to a consumer-ready product.
Many companies in this industry rely on approval from the Health Canada or the U.S. Food and Drug Administration (FDA), and the process can take years. There’s no guarantee that a drug in development will reach pharmacy shelves or that a new industrial pesticide will be cleared for public use. Some biotech companies funnel funds into projects that span years with nothing to show for it.
The recent scramble for a COVID-19 cure demonstrates the potential instability of a biotech investment. As dozens of companies rush to develop a viable vaccine, stocks in this sector are seeing a volatility surge as investors queue to back the right racehorse. But only one can win — and once a vaccine is approved, the other companies fighting to be first may see a drop in share prices.
Investors must be willing to wait months or years for biotech stock investments to pan out. And even then, there’s no guarantee of return.
Biotech stocks
From startups with high hopes to well-established international corporations, there are a number of options for investors interested in purchasing biotech stocks.
Helix BioPharma (TSX:HBP.TO)
Spectral Medical (TSX:EDT)
Medicenna Therapeutics (TSX:MDNA)
Trillium Therapeutics Inc. (TSX:TRIL)
StageZero Life Sciences (TSX:SZLS)
Aptose Biosciences (TSX:APS)
Oncolytics Biotech Inc. (TSX:ONC)
THC Biomed International (CSE:THC)
Amgen (NASDAQ: AMGN)
CVS Health (NYSE: CVS)
Novartis (NYSE: NVS)
Gilead Sciences (NASDAQ:GILD)
Do biotechnology stocks pay dividends?
Some do. For example, Amgen (NASDAQ: AMGN), CVS Health (NYSE: CVS) and Novartis (NYSE: NVS) all pay dividends to shareholders. As of the time of writing, Spectral Medical (TSX:EDT), Helix BioPharma (TSX:HBP.TO) and Medicenna Therapeutics (TSX:MDNA) do not pay dividends.
Are there any biotechnology ETFs that trade on Canadian stock exchanges?
As of the time of writing, no. To invest in biotechnology ETFs, you have to access stock exchanges outside Canada like the NASDAQ or NYSE in the US. There are several Canadian-based brokerages that offer access to international exchanges on which biotechnology ETFs trade including Interactive Brokers and Questrade.
Alternatively, you can also buy stocks in biotechnology companies that trade on Canadian stock exchanges like Helix BioPharma (TSX:HBP.TO) and Aptose Biosciences (TSX:APS).
Compare trading platforms to buy biotech stocks
1 - 6 of 6
Finder Score for stock trading platforms
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.
Biotechnology is rife with potential, but is often subject to strict regulations. Investor funds may be tied up for years and there’s no guarantee of a return.
To invest in biotech stocks, explore your brokerage account options across multiple platforms for the account best suited for your investment goals.
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
Shannon Terrell is a lead writer and spokesperson at NerdWallet and a former editor at Finder, specializing in personal finance. Her writing and analysis on investing and banking has been featured in Bloomberg, Global News, Yahoo Finance, GoBankingRates and Black Enterprise. She holds a bachelor’s degree in communications and English literature from the University of Toronto Mississauga. See full bio
's expertise
has written 42 Finder guides across topics including:
Stacie Hurst is an editor at Finder, specializing in loans, banking, investing and money transfers. She has a Bachelor of Arts in Psychology and Writing, and she has completed FP Canada Institute's Financial Management Course. Before working in the publishing industry, Stacie completed one year of law school in the United States. When not working, she can usually be found watching K-dramas or playing games with her friends and family. See full bio
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
